Clinical bottom line
Refractory autoimmune hemolytic anemia (AIHA) remains a challenging clinical entity with limited response to first-line corticosteroids and conventional immunosuppressants. Recent advancements highlight a growing understanding of the complex immunopathogenesis involving cytokine networks and immune dysregulation, which has spurred investigation into novel targeted therapies. Emerging options include interleukin-6 (IL-6) inhibitors, proteasome inhibitors, and therapeutic plasma exchange, offering potential benefit in refractory cases. However, evidence is largely derived from small series and mechanistic studies, underscoring the need for cautious interpretation and individualized treatment decisions.
What the evidence shows
AIHA is characterized by autoantibody-mediated red blood cell destruction, with refractory cases defined by failure to respond or relapse after standard corticosteroid therapy. Costa et al. (2025) provide a comprehensive review of pathogenetic networks in AIHA, emphasizing the role of B-cell hyperactivity, T-cell dysregulation, and proinflammatory cytokines such as IL-6 in sustaining hemolysis and immune activation. This mechanistic insight has catalyzed exploration of targeted agents beyond broad immunosuppression.
IL-6 blockade has emerged as a promising strategy given IL-6’s central role in inflammatory cascades and autoantibody production. Zhao et al. (2026) discuss preclinical and early clinical data supporting IL-6 inhibitors in hemolytic anemias, including refractory AIHA, where IL-6-driven inflammation contributes to disease persistence. Although formal clinical trials are pending, case reports suggest potential efficacy in steroid-refractory patients.
Proteasome inhibition, traditionally used in multiple myeloma, has also been repurposed for refractory AIHA. Hamdan et al. (2020) describe a case where bortezomib induced remission in AIHA secondary to multiple myeloma, highlighting its immunomodulatory effects on plasma cells producing pathogenic autoantibodies. This approach remains investigational but offers a rationale for targeting antibody-secreting cells in refractory disease.
Therapeutic plasma exchange (TPE) has been employed as adjunctive therapy in refractory warm AIHA, aiming to remove circulating autoantibodies and immune complexes. Anani et al. (2017) report on TPE’s utility in severe refractory cases, demonstrating transient hematologic improvement, though its role is generally supportive and not curative.
Jacobs et al. (2025) provide a systematic review of mixed AIHA, a subtype often refractory to standard therapies, underscoring the heterogeneity of clinical presentations and responses. This review reinforces the need for tailored approaches incorporating novel agents guided by underlying immunopathology.
Finally, Cotelingam et al. (2024) highlight infectious triggers such as Babesia that can complicate AIHA management and contribute to refractory courses, emphasizing the importance of identifying and treating secondary causes.
Caveats and uncertainty
The current evidence base for novel therapies in refractory AIHA is limited by small sample sizes, retrospective designs, and case reports rather than randomized controlled trials. The heterogeneity of AIHA subtypes and underlying etiologies complicates generalization of findings. Long-term safety and efficacy data for IL-6 inhibitors and proteasome inhibitors in AIHA are lacking, and their immunosuppressive effects may increase infection risk.
Therapeutic plasma exchange provides only transient benefit and requires specialized resources, limiting widespread applicability. Moreover, the optimal timing, frequency, and patient selection criteria for TPE remain undefined.
The interplay between infectious triggers and refractory AIHA necessitates thorough evaluation to avoid misattribution of treatment failure. The absence of standardized biomarkers to predict response to novel agents further complicates clinical decision-making.
How this may change practice
Clinicians managing refractory AIHA should consider expanding diagnostic evaluation to include cytokine profiling and assessment for secondary causes such as infections or hematologic malignancies. Incorporating emerging targeted therapies like IL-6 inhibitors may offer new avenues for patients unresponsive to steroids and conventional immunosuppressants, particularly when supported by mechanistic rationale and early clinical experience.
Proteasome inhibitors could be contemplated in refractory AIHA associated with plasma cell dyscrasias, though off-label use requires careful risk-benefit assessment. Therapeutic plasma exchange remains a valuable adjunct in severe, refractory cases but should be integrated within a multimodal treatment strategy.
Ultimately, multidisciplinary collaboration and enrollment in clinical trials investigating novel agents are encouraged to advance evidence and optimize outcomes in this difficult-to-treat population.